Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice

Shayne N. Hassler, Fatima B. Ahmad, Carolina C. Burgos-Vega, Scott A Boitano, Josef Vagner, Theodore J. Price, Gregory Dussor

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Pain is the most debilitating symptom of migraine. The cause of migraine pain likely requires activation of meningeal nociceptors. Mast cell degranulation, with subsequent meningeal nociceptor activation, has been implicated in migraine pathophysiology. Degranulating mast cells release serine proteases that can cleave and activate protease activated receptors. The purpose of these studies was to investigate whether protease activated receptor 2 is a potential generator of nociceptive input from the meninges by using selective pharmacological agents and knockout mice. Methods: Ratiometric Ca++ imaging was performed on primary trigeminal and dural cell cultures after application of 2at-LIGRL-NH2, a specific protease activated receptor 2 agonist. Cutaneous hypersensitivity and facial grimace was measured in wild-type and protease activated receptor 2−/− mice after dural application of 2at-LIGRL-NH2 or compound 48-80, a mast cell degranulator. Behavioral experiments were also conducted in mice after dural application of 2at-LIGRL-NH2 (2AT) in the presence of either C391, a selective protease activated receptor 2 antagonist, or sumatriptan. Results: 2at-LIGRL-NH2 evoked Ca2+ signaling in mouse trigeminal neurons, dural fibroblasts and in meningeal afferents. Dural application of 2at-LIGRL-NH2 or 48-80 caused dose-dependent grimace behavior and mechanical allodynia that were attenuated by either local or systemic application of C391 as well as in protease activated receptor 2−/− mice. Nociceptive behavior after dural injection of 2at-LIGRL-NH2 was also attenuated by sumatriptan. Conclusions: Functional protease activated receptor 2 receptors are expressed on both dural afferents and fibroblasts and activation of dural protease activated receptor 2 produces migraine-like behavioral responses. Protease activated receptor 2 may link resident immune cells to meningeal nociceptor activation, driving migraine-like pain and implicating protease activated receptor 2 as a therapeutic target for migraine in humans.

Original languageEnglish (US)
JournalCephalalgia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

PAR-2 Receptor
Migraine Disorders
Pain
Nociceptors
Mast Cells
Sumatriptan
Fibroblasts
Proteinase-Activated Receptors
p-Methoxy-N-methylphenethylamine
Cell Degranulation
Meninges
Hyperalgesia
Serine Proteases
Knockout Mice
Hypersensitivity
Cell Culture Techniques
Pharmacology
Neurons

Keywords

  • dural nociceptor
  • mast cell
  • migraine
  • Protease activated receptor 2 (PAR2)
  • trigeminal nerve

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice. / Hassler, Shayne N.; Ahmad, Fatima B.; Burgos-Vega, Carolina C.; Boitano, Scott A; Vagner, Josef; Price, Theodore J.; Dussor, Gregory.

In: Cephalalgia, 01.01.2018.

Research output: Contribution to journalArticle

Hassler, Shayne N. ; Ahmad, Fatima B. ; Burgos-Vega, Carolina C. ; Boitano, Scott A ; Vagner, Josef ; Price, Theodore J. ; Dussor, Gregory. / Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice. In: Cephalalgia. 2018.
@article{eb615b0cdffa4dc5bcd1e2a904005b62,
title = "Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice",
abstract = "Background: Pain is the most debilitating symptom of migraine. The cause of migraine pain likely requires activation of meningeal nociceptors. Mast cell degranulation, with subsequent meningeal nociceptor activation, has been implicated in migraine pathophysiology. Degranulating mast cells release serine proteases that can cleave and activate protease activated receptors. The purpose of these studies was to investigate whether protease activated receptor 2 is a potential generator of nociceptive input from the meninges by using selective pharmacological agents and knockout mice. Methods: Ratiometric Ca++ imaging was performed on primary trigeminal and dural cell cultures after application of 2at-LIGRL-NH2, a specific protease activated receptor 2 agonist. Cutaneous hypersensitivity and facial grimace was measured in wild-type and protease activated receptor 2−/− mice after dural application of 2at-LIGRL-NH2 or compound 48-80, a mast cell degranulator. Behavioral experiments were also conducted in mice after dural application of 2at-LIGRL-NH2 (2AT) in the presence of either C391, a selective protease activated receptor 2 antagonist, or sumatriptan. Results: 2at-LIGRL-NH2 evoked Ca2+ signaling in mouse trigeminal neurons, dural fibroblasts and in meningeal afferents. Dural application of 2at-LIGRL-NH2 or 48-80 caused dose-dependent grimace behavior and mechanical allodynia that were attenuated by either local or systemic application of C391 as well as in protease activated receptor 2−/− mice. Nociceptive behavior after dural injection of 2at-LIGRL-NH2 was also attenuated by sumatriptan. Conclusions: Functional protease activated receptor 2 receptors are expressed on both dural afferents and fibroblasts and activation of dural protease activated receptor 2 produces migraine-like behavioral responses. Protease activated receptor 2 may link resident immune cells to meningeal nociceptor activation, driving migraine-like pain and implicating protease activated receptor 2 as a therapeutic target for migraine in humans.",
keywords = "dural nociceptor, mast cell, migraine, Protease activated receptor 2 (PAR2), trigeminal nerve",
author = "Hassler, {Shayne N.} and Ahmad, {Fatima B.} and Burgos-Vega, {Carolina C.} and Boitano, {Scott A} and Josef Vagner and Price, {Theodore J.} and Gregory Dussor",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/0333102418779548",
language = "English (US)",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice

AU - Hassler, Shayne N.

AU - Ahmad, Fatima B.

AU - Burgos-Vega, Carolina C.

AU - Boitano, Scott A

AU - Vagner, Josef

AU - Price, Theodore J.

AU - Dussor, Gregory

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Pain is the most debilitating symptom of migraine. The cause of migraine pain likely requires activation of meningeal nociceptors. Mast cell degranulation, with subsequent meningeal nociceptor activation, has been implicated in migraine pathophysiology. Degranulating mast cells release serine proteases that can cleave and activate protease activated receptors. The purpose of these studies was to investigate whether protease activated receptor 2 is a potential generator of nociceptive input from the meninges by using selective pharmacological agents and knockout mice. Methods: Ratiometric Ca++ imaging was performed on primary trigeminal and dural cell cultures after application of 2at-LIGRL-NH2, a specific protease activated receptor 2 agonist. Cutaneous hypersensitivity and facial grimace was measured in wild-type and protease activated receptor 2−/− mice after dural application of 2at-LIGRL-NH2 or compound 48-80, a mast cell degranulator. Behavioral experiments were also conducted in mice after dural application of 2at-LIGRL-NH2 (2AT) in the presence of either C391, a selective protease activated receptor 2 antagonist, or sumatriptan. Results: 2at-LIGRL-NH2 evoked Ca2+ signaling in mouse trigeminal neurons, dural fibroblasts and in meningeal afferents. Dural application of 2at-LIGRL-NH2 or 48-80 caused dose-dependent grimace behavior and mechanical allodynia that were attenuated by either local or systemic application of C391 as well as in protease activated receptor 2−/− mice. Nociceptive behavior after dural injection of 2at-LIGRL-NH2 was also attenuated by sumatriptan. Conclusions: Functional protease activated receptor 2 receptors are expressed on both dural afferents and fibroblasts and activation of dural protease activated receptor 2 produces migraine-like behavioral responses. Protease activated receptor 2 may link resident immune cells to meningeal nociceptor activation, driving migraine-like pain and implicating protease activated receptor 2 as a therapeutic target for migraine in humans.

AB - Background: Pain is the most debilitating symptom of migraine. The cause of migraine pain likely requires activation of meningeal nociceptors. Mast cell degranulation, with subsequent meningeal nociceptor activation, has been implicated in migraine pathophysiology. Degranulating mast cells release serine proteases that can cleave and activate protease activated receptors. The purpose of these studies was to investigate whether protease activated receptor 2 is a potential generator of nociceptive input from the meninges by using selective pharmacological agents and knockout mice. Methods: Ratiometric Ca++ imaging was performed on primary trigeminal and dural cell cultures after application of 2at-LIGRL-NH2, a specific protease activated receptor 2 agonist. Cutaneous hypersensitivity and facial grimace was measured in wild-type and protease activated receptor 2−/− mice after dural application of 2at-LIGRL-NH2 or compound 48-80, a mast cell degranulator. Behavioral experiments were also conducted in mice after dural application of 2at-LIGRL-NH2 (2AT) in the presence of either C391, a selective protease activated receptor 2 antagonist, or sumatriptan. Results: 2at-LIGRL-NH2 evoked Ca2+ signaling in mouse trigeminal neurons, dural fibroblasts and in meningeal afferents. Dural application of 2at-LIGRL-NH2 or 48-80 caused dose-dependent grimace behavior and mechanical allodynia that were attenuated by either local or systemic application of C391 as well as in protease activated receptor 2−/− mice. Nociceptive behavior after dural injection of 2at-LIGRL-NH2 was also attenuated by sumatriptan. Conclusions: Functional protease activated receptor 2 receptors are expressed on both dural afferents and fibroblasts and activation of dural protease activated receptor 2 produces migraine-like behavioral responses. Protease activated receptor 2 may link resident immune cells to meningeal nociceptor activation, driving migraine-like pain and implicating protease activated receptor 2 as a therapeutic target for migraine in humans.

KW - dural nociceptor

KW - mast cell

KW - migraine

KW - Protease activated receptor 2 (PAR2)

KW - trigeminal nerve

UR - http://www.scopus.com/inward/record.url?scp=85047905127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047905127&partnerID=8YFLogxK

U2 - 10.1177/0333102418779548

DO - 10.1177/0333102418779548

M3 - Article

C2 - 29848111

AN - SCOPUS:85047905127

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

ER -